Published January 30, 2022 | Version 1.0.0
Dataset Open

TomoBreast randomized clinical trial's lung-heart outcomes and mortality through the 2020 COVID-19 pandemic: data and software

  • 1. Centre hospitalier de Polynesie francaise
  • 2. UZ Brussel

Description

Dataset and R script to reproduce the analyses of the manuscript:

Vinh-Hung V, Gorobets O, Adriaenssens N, Van Parijs H, Storme G, Verellen D, Nguyen NP, Magne N, De Ridder M.

Lung-heart outcomes and mortality through the 2020 COVID-19 pandemic in a prospective cohort of breast cancer radiotherapy patients.

Cancers 2022; 14(24):6241. https:// doi.org/10.3390/cancers14246241

https://www.mdpi.com/2072-6694/14/24/6241

PubMed: PMID: 36551726

PMCID: PMC9777311

Info on the variables in file "aelq6_public.R"

reproduced in "aelq_2_3_readme.txt":

"aelq2_base2.txt" = baseline characteristics.

"aelq3.txt" = longitudinal maesurements.

Variables in "aelq2_base2.txt":

"aelq2_base2.txt" = baseline characteristics. 
# Age at randomization, years. 
# RTdose: cf TomoBreast papers. 
# 51 Gy = hypofractionated, simultaneous integrated boost
# 42 Gy = hypofractionated, no boost, mastectomy cases only
# 50 Gy = conventional, no boost, mastectomy cases only
# 66 Gy = conventional, sequential boost
# Weight kg, Height cm, 
# Detection 1=found by screening (senology follow-up/controle)
#     2=found by symptoms (pain, palpable)
#     9=unknown
# Smoker     0= Not smoker
#     1= Smoker
#     2=ex-smoker
# Mastectomy (and other binary coded) 1= yes
# chemosched 0=none
#     1= planned after RT (sequential)
#     2= prior to RT and is finished (sequential)
#     3= chemo is on-going or is planned to start with RT (concomitant)
# hormonetherapy     0=no
#     1=tamoxifen (nolvadex)
#     2=Femara (Letrozole)
#     3=zoladex
#     4=tamoxifen + zoladex
# Laterality 1,=Right, 2=Left, 3=Bilateral
# LengthFU: length of follow-up, days from randomization

"aelq3.txt" = longitudinal maesurements.
# "Nr" = Case ID
# "Time" in days from origin (origin =date of randomization), 
# if negative =before randomization
#    "KPS"       "Weight"    
# "Died"      "LocalRec"  "Metast"    "NewPrim"   = binary code, 0=no, 1=yes
# "fAEBreast" "fAEHeart"  "fAELung"   "fAEOther" 
# fAE = freedom from breast, heart, lung, other adverse event score
# "LVEF2" = ejection fraction, %
# "MacIver" = estimated cardiac strain

# the following are pulmonary function tests, untransformed units
# "FVC", "FEV1", "PEF", "VC", "TLC", "RV", "FRC", "Raw", "sRaw", "DLCO",
# "VA", "PF"

# "fDY", "fFA", "fPA" = freedom from dyspnea, from fatigue, from pain
# range 0 to 100 (best)
# see papers:

# Van Parijs, H.; Vinh-Hung, V.; Fontaine, C.; Storme, G.; Verschraegen, C.;
# Nguyen, D.M.; Adriaenssens, N.; Nguyen, N.P.; Gorobets, O.; De Ridder, M.
# Cardiopulmonary-related patient-reported outcomes in a randomized clinical
# trial of radiation therapy for breast cancer. BMC Cancer 2021, 21, 1177,
# doi:10.1186/s12885-021-08916-z.

# preprint:
# Van Parijs, H.; Cecilia-Joseph, E.; Gorobets, O.; Storme, G.; 
# Adriaenssens, N.; Heyndrickx, B.; Verschraegen, C.; Nguyen, N.P.;
# De Ridder, M.; Vinh-Hung, V. Lung-heart toxicity in a randomized 
# clinical trial of hypofractionated image guided radiation therapy for
# breast cancer. Preprints 2022, 202212, 0214.
# https://doi.org/10.20944/preprints202212.0214.v1


# "Year" = year of the observation
# example: randomized 1/1/2011, measurement done 1/31/2011, time = 30 days,
# Year =2011
#
 

Notes

Lung-heart toxicity in a randomized clinical trial of hypofractionated image guided radiation therapy for breast cancer.

Van Parijs H, Cecilia-Joseph E, Gorobets O, Storme G, Adriaenssens N, Heyndrickx B, Verschraegen C, Nguyen NP, De Ridder M, Vinh-Hung V.Front Oncol. 2023 Nov 20;13:1211544. doi: 10.3389/fonc.2023.1211544. eCollection 2023.PMID: 38053657 
 
https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1211544/full
 

Files

aelq2_base2.txt

Files (514.6 kB)

Name Size Download all
md5:b285fc4e80e1df6021e1337241fdee67
10.2 kB Preview Download
md5:1afe2f3acf791d8bd0b18bfa8703f14e
480.6 kB Preview Download
md5:9d51011e0525fd2adc9892bd8965c1bc
21.0 kB Download
md5:7183e5ca351fdc9db2da412b6949062c
2.7 kB Preview Download

Additional details

Related works

Is part of
Journal: 10.3389/fonc.2023.1211544 (DOI)
Journal: 10.3390/cancers14246241 (DOI)

References

  • Van Parijs, H.; Cecilia-Joseph, E.; Gorobets, O.; Storme, G.; Adriaenssens, N.; Heyndrickx, B.; Verschraegen, C.; Nguyen, N.P.; De Ridder, M.; Vinh-Hung, V. Lung-heart toxicity in a randomized clinical trial of hypofractionated image guided radiation therapy for breast cancer. Preprints 2022, 202212, 0214. doi: 10.20944/preprints202212.0214.v1
  • Vinh-Hung V, Gorobets O, Adriaenssens N, Van Parijs H, Storme G, Verellen D, Nguyen NP, Magne N, De Ridder M. Lung-Heart Outcomes and Mortality through the 2020 COVID-19 Pandemic in a Prospective Cohort of Breast Cancer Radiotherapy Patients. Cancers. 2022; 14(24):6241. https://doi.org/10.3390/cancers14246241
  • Lara PC, Nguyen NP, Macias-Verde D, Burgos-Burgos J, Arenas M, Zamagni A, Vinh-Hung V, Baumert BG, Motta M, Myint AS, Bonet M, Popescu T, Vuong T, Appalanaido GK, Trigo L, Karlsson U, Thariat J. Whole-lung Low Dose Irradiation for SARS-Cov2 Induced Pneumonia in the Geriatric Population: An Old Effective Treatment for a New Disease? Recommendation of the International Geriatric Radiotherapy Group. Aging Dis. 2020 May 9;11(3):489-493. doi: 10.14336/AD.2020.0506
  • Nguyen NP, Vinh-Hung V, Baumert B, Zamagni A, Arenas M, Motta M, Lara PC, Myint AS, Bonet M, Popescu T, Vuong T, Appalanaido GK, Trigo L, Karlsson U, Thariat J. Older Cancer Patients during the COVID-19 Epidemic: Practice Proposal of the International Geriatric Radiotherapy Group. Cancers (Basel) . 2020 May 19;12(5):1287. doi: 10.3390/cancers12051287.
  • Verbanck S, Van Parijs H, Schuermans D, Vinh-Hung V, Storme G, Fontaine C, De Ridder M, Verellen D, Vanderhelst E, Hanon S. Lung Restriction in Patients With Breast Cancer After Hypofractionated and Conventional Radiation Therapy: A 10-Year Follow-up. Int J Radiat Oncol Biol Phys. 2022 Jul 1;113(3):561-569. doi: 10.1016/j.ijrobp.2022.02.021
  • Van Parijs H, Vinh-Hung V, Fontaine C, Storme G, Verschraegen C, Nguyen DM, Adriaenssens N, Nguyen NP, Gorobets O, De Ridder M. Cardiopulmonary-related patient-reported outcomes in a randomized clinical trial of radiation therapy for breast cancer. BMC Cancer. 2021 Nov 4;21(1):1177. doi: 10.1186/s12885-021-08916-z
  • Heymann S, Dipasquale G, Nguyen NP, San M, Gorobets O, Leduc N, Verellen D, Storme G, Van Parijs H, De Ridder M, Vinh-Hung V. Two-Level Factorial Pre-TomoBreast Pilot Study of Tomotherapy and Conventional Radiotherapy in Breast Cancer: Post Hoc Utility of a Mean Absolute Dose Deviation Penalty Score. Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820947759. doi: 10.1177/1533033820947759.
  • Van Parijs H, Miedema G, Vinh-Hung V, Verbanck S, Adriaenssens N, Kerkhove D, Reynders T, Schuermans D, Leysen K, Hanon S, Van Camp G, Vincken W, Storme G, Verellen D, De Ridder M. Short course radiotherapy with simultaneous integrated boost for stage I-II breast cancer, early toxicities of a randomized clinical trial. Radiat Oncol. 2012 Jun 1;7:80. doi: 10.1186/1748-717X-7-80
  • Van Parijs H, Cecilia-Joseph E, Gorobets O, Storme G, Adriaenssens N, Heyndrickx B, Verschraegen C, Nguyen NP, De Ridder M, Vinh-Hung V. Lung-heart toxicity in a randomized clinical trial of hypofractionated image guided radiation therapy for breast cancer. Front Oncol. 2023 Nov 20;13:1211544. doi: 10.3389/fonc.2023.1211544. eCollection 2023.